News

Kiadis Pharma signs license agreement with Hospira to commercialize ATIR™ in Europe and Asia - Partnership would advance innovative stem cell transplant product 04-01-2011
Kiadis Pharma, a biopharmaceutical company based in The Netherlands, announced that it has entered into a licensing agreement with Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical company, to develop and commercialize Kiadis Pharma’s ATIR™. ATIR™ is a personalized hematology product... read more 

Kiadis Pharma receives IND approval from FDA to start pivotal clinical trial with ATIR™ 08-07-2010
Biopharmaceutical Company Kiadis Pharma announced today that it has received approval for its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to start the pivotal clinical study for its product ATIR™ in the United States. Kiadis Pharma is currently... read more 

ECTA

The ECTA (Enzyme Catalyzed Therapeutics Agents) platform is based upon using over-expressed endogenous enzymes to activate specifically designed small molecules into toxic products. The platform includes intellectual property on other over-expressed enzymes involved in various cancers.

 

Image Ecta

Kiadis Pharma

Entrada 231-234
1096 EG  Amsterdam
The Netherlands


T +31 (0)20 314 02 50
F +31 (0)20 314 02 51